Organon & Stock News

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sector ETF report for XPH

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating

With these shares at modest valuations, you can score some cheap long-term investments.

Smart Beta ETF report for XPH

Do you know your lipid profile? High cholesterol usually has no signs or symptoms. The only way to…

Organon & Co. (OGN) CEO Kevin Ali Presents at 42nd Annual Cowen Health Care Conference (Transcript)

Organon & Co sees its Relative Strength Rating enter the elite 90-plus level.

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Cowen 42nd Annual Healthcare Virtual Conference on Wednesday, March 9, 2022 at 9:10 a.m. EST. Investors, analysts, members of the media and the general public are invited to watch to a live video webcast of the presentation at https://www.organon.com/investor-relations/events-and-prese

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in

These two ETFs are built to deliver the most dividend income possible

Shares of Organon & Co. ( OGN , Financial) are up nearly 7% since the pharma company was spun off by Merck & Co. Inc. ( MRK , Financial) in the middle of 2021. And even bluer skies appear to be on the

Viatris was formed by the merger of Pfizer's Legacy Brands business Upjohn with generic drug developer Mylan.